David Lee McKinzie

Title: The Innovations of David Lee McKinzie

Introduction

David Lee McKinzie is an accomplished inventor based in Whitestown, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective opioid receptor antagonists. With a total of 2 patents to his name, McKinzie's work is focused on addressing critical health issues such as ethanol use disorder and related mental health conditions.

Latest Patents

McKinzie's latest patents include a kappa selective opioid receptor antagonist, which is designed to be useful for treating ethanol use disorder withdrawal, anxiety, depression, and schizophrenia as independent comorbid conditions. The specific formulation described in one of his patents is (S)-3-Fluoro-4-[4-[2-(3,5-dimethylphenyl)pyrrolidin-1-yl-methyl]phenoxy]benzamide or a pharmaceutically acceptable salt thereof. This innovative approach aims to provide effective treatment options for individuals struggling with these complex health challenges.

Career Highlights

David Lee McKinzie is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to collaborate with other talented professionals in the field, contributing to the advancement of medical science and patient care.

Collaborations

Some of McKinzie's notable coworkers include Nuria Diaz Buezo and Concepcion Pedregal-Tercero. Their collaborative efforts have played a vital role in the development of new therapeutic solutions.

Conclusion

David Lee McKinzie's innovative work in the pharmaceutical industry highlights the importance of research and development in addressing significant health issues. His contributions through his patents reflect a commitment to improving the lives of individuals affected by complex medical conditions.